Zhangzhou Pientzehuang Pharmaceutical., Ltd (SHA: 600436)

Zhangzhou Pientzehuang Pharmaceutical., Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	8,921	1,159	2,496	7,097	5,168	4,263
Short-Term Investments	279.33	9,014	6,202	-	-	-
Trading Asset Securities	-	-	-	8.8	0.01	0.02
Cash & Short-Term Investments	9,201	10,173	8,698	7,106	5,168	4,263
Cash Growth	-7.85%	16.95%	22.42%	37.48%	21.23%	53.00%
Accounts Receivable	913.34	1,021	859.49	673.3	574.34	486.93
Other Receivables	95.5	65.15	107.94	134.95	70.11	208.5
Receivables	1,107	1,086	967.43	808.25	644.45	695.43
Inventory	4,539	3,379	2,628	2,438	2,191	2,097
Prepaid Expenses	8.2	14.05	4.55	20.68	-	24.54
Other Current Assets	270.54	447.9	406.61	261.36	292.18	271.95
Total Current Assets	15,126	15,100	12,705	10,633	8,296	7,352
Property, Plant & Equipment	646.99	614.62	465.62	400.14	274.96	253.4
Long-Term Investments	562.56	631.98	673.7	799.87	979.2	896.2
Other Intangible Assets	279.08	291.09	319.37	220.96	259.38	155.66
Long-Term Deferred Tax Assets	190.25	187.31	167.26	166.98	85.41	76.2
Long-Term Deferred Charges	25.46	29.99	37.65	44.19	49.42	32.83
Other Long-Term Assets	216.72	225.4	235.41	255.59	261.16	44.21
Total Assets	17,047	17,080	14,604	12,521	10,206	8,811
Accounts Payable	500.67	667.92	464.9	386.99	239.94	260.56
Accrued Expenses	611.6	685.98	345.39	342.14	139.24	249.14
Short-Term Debt	1,021	989.93	970.96	775.79	718.38	696.85
Current Portion of Long-Term Debt	2.59	1.87	-	-	-	-
Current Portion of Leases	24.98	31.86	29.21	22.75	-	-
Current Income Taxes Payable	140.61	142.65	72.93	108.96	77.56	220.48
Current Unearned Revenue	86.79	237.1	468.57	326.56	283.75	201.76
Other Current Liabilities	138.8	125.8	158.22	173.9	341.46	118.21
Total Current Liabilities	2,527	2,883	2,510	2,137	1,800	1,747
Long-Term Debt	49.17	35.44	-	-	-	-
Long-Term Leases	108.95	107.29	108.8	86.67	-	-
Long-Term Unearned Revenue	21.94	17.67	17.01	20.24	14.68	14.72
Long-Term Deferred Tax Liabilities	22.49	30.02	61.09	74.52	47.47	47.83
Other Long-Term Liabilities	37.76	51.35	48.54	32.88	57.09	2.54
Total Liabilities	2,802	3,160	2,780	2,384	1,949	1,841
Common Stock	603.32	603.32	603.32	603.32	603.32	603.32
Additional Paid-In Capital	1,095	1,095	1,094	1,086	1,085	1,084
Retained Earnings	11,924	11,602	9,559	7,816	5,862	4,686
Comprensive Income & Other	47.3	76.6	74.41	200.05	311.57	257.5
Total Common Equity	13,670	13,376	11,330	9,705	7,862	6,631
Minority Interest	575.29	544.17	493.97	432.07	394.39	338.41
Shareholders' Equity	14,245	13,920	11,824	10,138	8,257	6,970
Total Liabilities & Equity	17,047	17,080	14,604	12,521	10,206	8,811
Total Debt	1,207	1,166	1,109	885.21	718.38	696.85
Net Cash (Debt)	7,994	9,007	7,589	6,220	4,450	3,567
Net Cash Growth	-10.62%	18.67%	22.01%	39.78%	24.77%	63.08%
Net Cash Per Share	13.26	14.94	12.59	10.31	7.37	5.92
Filing Date Shares Outstanding	603.32	603.32	603.32	603.32	603.32	603.32
Total Common Shares Outstanding	603.32	603.32	603.32	603.32	603.32	603.32
Working Capital	12,599	12,217	10,195	8,496	6,496	5,605
Book Value Per Share	22.66	22.17	18.78	16.09	13.03	10.99
Tangible Book Value	13,390	13,085	11,011	9,484	7,603	6,476
Tangible Book Value Per Share	22.19	21.69	18.25	15.72	12.60	10.73
Buildings	415.43	400.13	331.45	332.55	331.29	292.92
Machinery	362.34	345.33	324.4	300.25	263.39	222.81
Construction In Progress	186.51	157.19	60.78	14.94	1.03	11.16

Source: S&P Capital IQ. Standard template. Financial Sources.